Harvard’s Aaron Kesselheim resigns from expert panel in wake of aducanumab OK, blasting FDA for ‘worst drug approval decision in recent U.S. history'

Max Gelman

Senior Editor

A third member of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee has resigned in the wake of Biogen’s controversial Aduhelm approval, slamming …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

view job offer post your job now

TRENDING NOW

Harvard’s Aaron Kesselheim resigns from expert panel in wake of aducanumab OK, blasting FDA for ‘worst drug approval decision in recent U.S. history'

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Har­vard’s Aaron Kessel­heim re­signs from ex­pert pan­el in wake of ad­u­canum­ab OK, blast­ing FDA for ‘worst drug ap­proval de­ci­sion in re­cent U.S. his­to­ry'

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Harvard’s Aaron Kesselheim resigns from expert panel in wake of aducanumab OK, blasting FDA for ‘worst drug approval decision in recent U.S. history'